未登录

D

David Brown

State University System of Florida

H指数:20

被引数:1,819

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2024-03-183

PRE

Strain and Defect Evolution of Si1-xGex/Si Heterostructures Grown by Pulsed Laser Induced Epitaxy

脉冲激光诱导外延生长的Si1-xGex/Si异质结构的应变和缺陷演化

SURFACES AND INTERFACES

IF6.3

2022-08-012

PRE

Pulsed laser melting of implant amorphized Si1-xGex thin films

APPLIED SURFACE SCIENCE

IF6.9

2021-10-012

PREAI

Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2021-07-165

OA

Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2021-03-185

OA

The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2021-01-2011

OAAI

Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-12-0114

OAAI

The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model

在中空纤维感染模型中，磷霉素和美罗培南的组合对铜绿假单胞菌PAO1具有协同作用

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-12-0134

OAAI

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

IF4.7

2015-12-3162

OAAI

Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

抗生素耐药性破坏者: 重新利用的药物可以填补抗生素发现的空白吗？

NATURE REVIEWS DRUG DISCOVERY

IF101.8

2015-10-23290

PREAI

Pharmacodynamic Evaluation of the Activities of Six Parenteral Vancomycin Products Available in the United States

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-01-0110

OAAI

Combination Treatment With Meropenem Plus Levofloxacin Is Synergistic Against Pseudomonas aeruginosa Infection in a Murine Model of Pneumonia

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2014-10-3135

OAAI

Impact of Meropenem in Combination with Tobramycin in a Murine Model of Pseudomonas aeruginosa Pneumonia

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2013-06-0149

OAAI

Impact of Spores on the Comparative Efficacies of Five Antibiotics for Treatment of Bacillus anthracis in an In Vitro Hollow Fiber Pharmacodynamic Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2012-03-0118

OAAI

Differential Effects of Linezolid and Ciprofloxacin on Toxin Production by Bacillus anthracis in an In Vitro Pharmacodynamic System

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2012-01-0119

OAAI

Resistance Emergence Mechanism and Mechanism of Resistance Suppression by Tobramycin for Cefepime for Pseudomonas aeruginosa

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2012-01-0156

OAAI

Comparative Efficacies of Candidate Antibiotics against Yersinia pestis in an In Vitro Pharmacodynamic Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2011-06-0113

OAAI

Impact of Spore Biology on the Rate of Kill and Suppression of Resistance in Bacillus anthracis

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2009-11-017

OAAI

Synthesis of tert-Butyl 6-Oxo-2-azaspiro[3.3]heptane-2-carboxylate

ORGANIC LETTERS

IF5

2009-08-2027

PREAI

Is 60 Days of Ciprofloxacin Administration Necessary for Postexposure Prophylaxis for Bacillus anthracis?

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2008-11-0124

OAAI